

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OP PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING	DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/938,884	08/24/2001		Arthur Dale Ericsson	IBRPAT007US	2533	
7	590	02/04/2003				
John R. Casperson				EXAMINER		
PO Box 2174			JONES, DAMERON			
Friendswood,	ΓX 77549		JOINES, DAIVIERON			
				ART UNIT	PAPER NUMBER	
				1616	<u> </u>	
				DATE MAILED: 02/04/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application N .	Applicant(s)					
•		09/938,884	ERICSSON, ARTHUR DALE					
	Office Action Summary	Examiner	Art Unit					
		D. L. Jones	1616					
The MAILING DATE f this communication appears n the cover sheet with the correspondence address Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).								
Status 1)	Responsive to communication(s) filed on							
'/⊔ 2a)□		— : s action is non-final.						
3)	,—		osecution as to th	e merits is				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims								
4)⊠ Claim(s) <u>1-18</u> is/are pending in the application.								
4a) Of the above claim(s) is/are withdrawn from consideration.								
5)[5) Claim(s) is/are allowed.							
6)□	6) Claim(s) is/are rejected.							
7)	7) Claim(s) is/are objected to.							
8)⊠	Claim(s) 1-18 are subject to restriction and/or e	election requirement.						
Applicat	ion Papers 🔆							
9) The specification is objected to by the Examiner.								
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.								
If approved, corrected drawings are required in reply to this Office action.								
12) The oath or declaration is objected to by the Examiner.								
Priority under 35 U.S.C. §§ 119 and 120								
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a) ☐ All b) ☐ Some * c) ☐ None of:								
	1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No							
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.								
Attachment(s)								
2) Notic	te of References Cited (PTO-892) te of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	(PTO-413) Paper No(Patent Application (PT					



Application/Control Number: 09/938,884

Art Unit: 1616

RESTRICTION INTO GROUPS

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - Claims 1-9, drawn to composition comprising a living pathogen-targeting organic moiety and a radioisotope, classified in class 424, subclass 1.65.
 - II. Claims 10-18, drawn to methods of treating infectious diseases, classified in class 424, subclass 9.1.
- 2. The inventions are distinct, each from the other because of the following reasons: Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the composition used in the method may be an antibody, virus, or any other living blood-borne pathogen.
- 3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.
- 4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Application/Control Number: 09/938,884

Art Unit: 1616

ELECTION OF SPECIES (for search purposes only)

5. Claims 1-18 encompass a multitude of living pathogen-targeting organic moieties. In particular, the targeting moiety may be a virus, antibody, or any other living pathogen known to man. Thus, Applicant is respectfully requested to elect a single disclosed species, even though this requirement is traversed.

Note: The Examiner respectfully requests that the Applicant elect a single disclose species from within the elected group. If Group I is elected, Applicant is respectfully requested to elect a living pathogen-targeting organic moiety, a radioisotope, and a support. If Group II is elected, Applicant is respectfully requested to elect a blood-borne pathogen, a radioisotope, and a support. In addition, Applicant is respectfully requested to state which claims are drawn to the elected species.

- 6. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.
- 7. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. L. Jones whose telephone number is (703) 308-4640. The examiner can normally be reached on Mon.-Fri. (alternate Mon.), 6:45 a.m. - 4:15 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jose' Dees can be reached on (703) 308- 4628. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4556 for regular communications and (703) 308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Primary Examiner
Art Unit 1616

January 31, 2003